Decreased human epididymis protein 4 (HE4) plasma levels were reported in cystic fibrosis (CF) patients under CFTR potentiator ivacaftor therapy, which inversely correlated with lung function improvement. In this study, we investigated whether HE4 expression was affected via modulation of CFTR function in CF bronchial epithelial (CFBE) cells in vitro. HE4 protein levels were measured in the supernatants of CFBE 41o- cells expressing F508del-CFTR or wild-type CFTR (wt-CFTR) after administration of lumacaftor/ivacaftor or tezacaftor/ivacaftor, while HE4 expression in CFBE 41o- cells were also analyzed following application of adenylate cyclase activators Forskolin/IBMX or CFTRinh172. The effect of all of these compounds on CFTR function was monitored by the whole-cell patch-clamp technique. Induced HE4 expression was studied with interleukin-6 (IL-6) in F508del-CFTR CFBE 41o- cells under TNF-α stimulation for 1 h up to 1 week in duration. In parallel, plasma HE4 was determined in CF subjects homozygous for p.Phe508del-CFTR mutation receiving lumacaftor/ivacaftor (Orkambi®) therapy. NF-κB-mediated signaling was observed via the nuclear translocation of p65 subunit by fluorescence microscopy together with the analysis of IL-6 expression by an immunoassay. In addition, HE4 expression was examined after NF-κB pathway inhibitor BAY 11-7082 treatment with or without CFTR modulators. CFTR modulators partially restored the activity of F508del-CFTR and reduced HE4 concentration was found in F508del-CFTR CFBE 41o- cells that was close to what we observed in CFBE 41o- cells with wt-CFTR. These data were in agreement with decreased plasma HE4 concentrations in CF patients treated with Orkambi®. Furthermore, CFTR inhibitor induced elevated HE4 levels, while CFTR activator Forskolin/IBMX downregulated HE4 in the cell cultures and these effects were more pronounced in the presence of CFTR modulators. Higher activation level of baseline and TNF-α stimulated NF-κB pathway was detected in F508del-CFTR vs. wt-CFTR CFBE 41o- cells that was substantially reduced by CFTR modulators based on lower p65 nuclear positivity and IL-6 levels. Finally, HE4 expression was upregulated by TNF-α with elevated IL-6, and both protein levels were suppressed by combined administration of NF-κB pathway inhibitor and CFTR modulators in CFBE 41o- cells. In conclusion, CFTR dysfunction contributes to abnormal HE4 expression via NF-κB in CF.

Department of Biology and Medical Genetics Charles University 2nd Faculty of Medicine and Motol University Hospital Prague Czech

Department of Biophysics and Cell Biology Faculty of Medicine University of Debrecen Debrecen Hungary

Department of Laboratory Medicine Faculty of Medicine University of Debrecen Debrecen Hungary

Department of Pediatrics Faculty of Medicine University of Debrecen Debrecen Hungary

Department of Pharmaceutical Technology Faculty of Pharmacy University of Debrecen Debrecen Hungary

Division of Clinical Genetics Department of Laboratory Medicine Faculty of Medicine University of Debrecen Debrecen Hungary

Faculty of Sciences BioISI Biosystems and Integrative Sciences Institute University of Lisboa Lisboa Portugal

Kálmán Laki Doctoral School of Biomedical and Clinical Sciences Faculty of Medicine University of Debrecen Debrecen Hungary

000      

00000naa a2200000 a 4500

001      

bmc21017759

003      

CZ-PrNML

005      

20210729104016.0

007      

ta

008      

210726s2021 sz f 000 0|eng||

009      

AR

024    7_

$a 10.3389/fphar.2021.592184 $2 doi

035    __

$a (PubMed)34054511

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a sz

100    1_

$a Bene, Zsolt $u Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary $u Department of Pediatrics, Faculty of Medicine, University of Debrecen, Debrecen, Hungary $u Kálmán Laki Doctoral School of Biomedical and Clinical Sciences, Faculty of Medicine, University of Debrecen, Debrecen, Hungary

245    10

$a Enhanced Expression of Human Epididymis Protein 4 (HE4) Reflecting Pro-Inflammatory Status Is Regulated by CFTR in Cystic Fibrosis Bronchial Epithelial Cells / $c Z. Bene, Z. Fejes, TG. Szanto, F. Fenyvesi, J. Váradi, LA. Clarke, G. Panyi, M. Macek, MD. Amaral, I. Balogh, B. Nagy

520    9_

$a Decreased human epididymis protein 4 (HE4) plasma levels were reported in cystic fibrosis (CF) patients under CFTR potentiator ivacaftor therapy, which inversely correlated with lung function improvement. In this study, we investigated whether HE4 expression was affected via modulation of CFTR function in CF bronchial epithelial (CFBE) cells in vitro. HE4 protein levels were measured in the supernatants of CFBE 41o- cells expressing F508del-CFTR or wild-type CFTR (wt-CFTR) after administration of lumacaftor/ivacaftor or tezacaftor/ivacaftor, while HE4 expression in CFBE 41o- cells were also analyzed following application of adenylate cyclase activators Forskolin/IBMX or CFTRinh172. The effect of all of these compounds on CFTR function was monitored by the whole-cell patch-clamp technique. Induced HE4 expression was studied with interleukin-6 (IL-6) in F508del-CFTR CFBE 41o- cells under TNF-α stimulation for 1 h up to 1 week in duration. In parallel, plasma HE4 was determined in CF subjects homozygous for p.Phe508del-CFTR mutation receiving lumacaftor/ivacaftor (Orkambi®) therapy. NF-κB-mediated signaling was observed via the nuclear translocation of p65 subunit by fluorescence microscopy together with the analysis of IL-6 expression by an immunoassay. In addition, HE4 expression was examined after NF-κB pathway inhibitor BAY 11-7082 treatment with or without CFTR modulators. CFTR modulators partially restored the activity of F508del-CFTR and reduced HE4 concentration was found in F508del-CFTR CFBE 41o- cells that was close to what we observed in CFBE 41o- cells with wt-CFTR. These data were in agreement with decreased plasma HE4 concentrations in CF patients treated with Orkambi®. Furthermore, CFTR inhibitor induced elevated HE4 levels, while CFTR activator Forskolin/IBMX downregulated HE4 in the cell cultures and these effects were more pronounced in the presence of CFTR modulators. Higher activation level of baseline and TNF-α stimulated NF-κB pathway was detected in F508del-CFTR vs. wt-CFTR CFBE 41o- cells that was substantially reduced by CFTR modulators based on lower p65 nuclear positivity and IL-6 levels. Finally, HE4 expression was upregulated by TNF-α with elevated IL-6, and both protein levels were suppressed by combined administration of NF-κB pathway inhibitor and CFTR modulators in CFBE 41o- cells. In conclusion, CFTR dysfunction contributes to abnormal HE4 expression via NF-κB in CF.

655    _2

$a časopisecké články $7 D016428

700    1_

$a Fejes, Zsolt $u Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary $u Kálmán Laki Doctoral School of Biomedical and Clinical Sciences, Faculty of Medicine, University of Debrecen, Debrecen, Hungary

700    1_

$a Szanto, Tibor Gabor $u Department of Biophysics and Cell Biology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary

700    1_

$a Fenyvesi, Ferenc $u Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, Debrecen, Hungary

700    1_

$a Váradi, Judit $u Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, Debrecen, Hungary

700    1_

$a Clarke, Luka A $u Faculty of Sciences, BioISI-Biosystems and Integrative Sciences Institute, University of Lisboa, Lisboa, Portugal

700    1_

$a Panyi, Gyorgy $u Department of Biophysics and Cell Biology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary

700    1_

$a Macek, Milan $u Department of Biology and Medical Genetics, Charles University-2nd Faculty of Medicine and Motol University Hospital, Prague, Czech

700    1_

$a Amaral, Margarida D $u Faculty of Sciences, BioISI-Biosystems and Integrative Sciences Institute, University of Lisboa, Lisboa, Portugal

700    1_

$a Balogh, István $u Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary $u Division of Clinical Genetics, Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary

700    1_

$a Nagy, Béla $u Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary $u Kálmán Laki Doctoral School of Biomedical and Clinical Sciences, Faculty of Medicine, University of Debrecen, Debrecen, Hungary

773    0_

$w MED00174597 $t Frontiers in pharmacology $x 1663-9812 $g Roč. 12, č. - (2021), s. 592184

856    41

$u https://pubmed.ncbi.nlm.nih.gov/34054511 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y - $z 0

990    __

$a 20210726 $b ABA008

991    __

$a 20210729104015 $b ABA008

999    __

$a ind $b bmc $g 1676412 $s 1138201

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2021 $b 12 $c - $d 592184 $e 20210514 $i 1663-9812 $m Frontiers in pharmacology $n Front Pharmacol $x MED00174597

LZP    __

$a Pubmed-20210726